Corcept Therapeutics Incorporated (CORT) Income Statement
CORT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCORT revenue and net income
Where CORT's revenue goes
2025Each bar shows an amount and its share of revenue. CORT kept 13.1% of revenue as net income.
CORT profit margins
CORT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +12.8% | +23.7% | +16.6% | +31.2% |
| Gross profit | +12.7% | +23.6% | +16.5% | +31.4% |
| Operating income | −67.3% | −26.5% | −19.0% | — |
| Net income | −28.7% | −0.6% | −1.2% | — |
| EPS (diluted) | −33.9% | −2.3% | −5.4% | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CORT quarterly EPS vs estimates
Corcept Therapeutics beat the analyst EPS estimate in 5 of the last 8 quarters. Next report: November 3, 2026 (estimate $0.68).
CORT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M | $353.9M | $306.5M | $251.2M | $159.2M | $81.3M |
| Cost of revenue | $13.0M | $10.9M | $6.5M | $5.4M | $5.3M | $5.6M | $5.5M | $5.2M | $3.6M | $2.1M |
| Gross profit | $748.4M | $664.2M | $475.9M | $396.5M | $360.7M | $348.3M | $301.0M | $246.0M | $155.6M | $79.3M |
| Research & development | $254.9M | $246.9M | $184.4M | $131.0M | $113.9M | $114.8M | $89.0M | $75.2M | $40.4M | $23.8M |
| Sales, general & admin | $448.7M | $280.3M | $184.3M | $152.8M | $122.4M | $105.3M | $100.4M | $81.3M | $62.4M | $45.2M |
| Total operating expenses | $703.6M | $527.2M | $368.6M | $283.8M | $236.2M | $220.1M | $189.4M | $156.5M | $102.8M | $69.1M |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M | $128.2M | $111.6M | $89.5M | $52.9M | $10.2M |
| Interest income | $21.7M | $24.5M | $17.3M | $3.6M | $529,000 | $3.4M | $5.1M | $2.7M | $49,000 | $1.9M |
| Interest expense | — | — | — | $3.6M | $3.6M | $5.6M | $5.1M | $2.7M | $49,000 | $2.0M |
| Income before taxes | $66.5M | $161.5M | $124.6M | $116.2M | $125.0M | $131.6M | $116.7M | $92.2M | $52.8M | $8.1M |
| Income taxes | −$33.2M | $20.3M | $18.4M | $14.8M | $12.5M | $25.6M | $22.5M | $16.7M | −$76.3M | $0 |
| Net income | $99.7M | $139.7M | $106.1M | $101.4M | $112.5M | $106.0M | $94.2M | $75.4M | $129.1M | $8.1M |
| EBITDA | $68.4M | $162.8M | $126.9M | $115.6M | $127.5M | $130.4M | $113.8M | $89.7M | $53.0M | $10.3M |
| EPS (diluted) | $0.82 | $1.24 | $0.95 | $0.88 | $1.09 | $1.08 | $1.09 | $0.79 | $0.45 | $0.07 |
| Gross margin | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% | 97.8% | 97.5% |
| Operating margin | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% | 33.2% | 12.5% |
| Net margin | 13.1% | 20.7% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% | 81.1% | 10.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $256.1M | $164.9M | $202.1M | $207.6M | $194.4M | $157.2M | $181.9M | $182.5M | $163.8M | $146.8M | $135.4M | $123.6M |
| Cost of revenue | $4.1M | $2.9M | $2.5M | $4.6M | $3.4M | $2.4M | $3.0M | $2.9M | $2.5M | $2.5M | $1.9M | $1.6M |
| Gross profit | $252.1M | $162.0M | $199.6M | $203.0M | $191.0M | $154.8M | $178.9M | $179.7M | $161.3M | $144.3M | $133.5M | $122.0M |
| Research & development | $53.9M | $66.3M | $64.9M | $68.8M | $60.5M | $60.7M | $70.3M | $59.3M | $58.7M | $58.5M | $54.7M | $45.5M |
| Sales, general & admin | $156.9M | $145.4M | $130.2M | $124.0M | $103.9M | $90.7M | $83.4M | $73.7M | $66.9M | $56.3M | $47.2M | $45.3M |
| Total operating expenses | $210.8M | $211.6M | $195.1M | $192.8M | $164.3M | $151.4M | $153.7M | $133.1M | $125.7M | $114.8M | $101.9M | $90.8M |
| Operating income | $41.3M | −$49.6M | $4.5M | $10.2M | $26.7M | $3.4M | $25.3M | $46.6M | $35.6M | $29.5M | $31.7M | $31.2M |
| Interest income | $4.6M | $4.9M | $5.4M | $5.0M | $5.0M | $6.2M | $6.7M | $6.3M | $6.0M | $5.5M | $5.1M | $5.2M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $3.6M | — |
| Income before taxes | $45.9M | −$44.7M | $9.9M | $15.2M | $31.7M | $9.6M | $32.0M | $52.9M | $41.6M | $35.0M | $36.8M | $36.4M |
| Income taxes | −$2.9M | −$13.5M | −$14.4M | −$4.4M | −$3.5M | −$10.9M | $1.2M | $5.7M | $6.1M | $7.2M | $5.5M | $5.0M |
| Net income | $42.1M | −$31.2M | $24.3M | $19.7M | $35.1M | $20.5M | $30.4M | $46.7M | $35.5M | $27.8M | $31.4M | $31.4M |
| EBITDA | $46.8M | −$44.1M | $10.4M | $15.7M | $32.2M | $10.1M | $32.4M | $53.4M | $41.9M | $35.2M | $37.4M | $36.7M |
| EPS (diluted) | $0.36 | −$0.30 | $0.20 | $0.16 | $0.29 | $0.17 | $0.26 | $0.41 | $0.32 | $0.25 | $0.28 | $0.28 |
| Gross margin | 98.4% | 98.3% | 98.7% | 97.8% | 98.2% | 98.5% | 98.4% | 98.4% | 98.5% | 98.3% | 98.6% | 98.7% |
| Operating margin | 16.1% | −30.1% | 2.2% | 4.9% | 13.7% | 2.2% | 13.9% | 25.5% | 21.7% | 20.1% | 23.4% | 25.2% |
| Net margin | 16.5% | −18.9% | 12.0% | 9.5% | 18.1% | 13.1% | 16.7% | 25.6% | 21.7% | 18.9% | 23.2% | 25.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CORT's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CORT financial results
In fiscal year 2025 (ended December 31, 2025), Corcept Therapeutics reported revenue of $761.4 million, up 12.8% from the year before. It had net income of $99.7 million (down 28.7%), a net profit margin of 13.1%. Diluted earnings per share came to $0.82. Over five years revenue grew at an average rate of 16.6% a year.
See the CORT stock overview for the latest quote and news, or the CORT chart for price history and technical indicators.
CORT income statement FAQ
What is Corcept Therapeutics's annual revenue?
Corcept Therapeutics reported total revenue of $761.4 million for fiscal year 2025, which ended on December 31, 2025. That was up 12.8% from $675.0 million the previous year.
Is Corcept Therapeutics profitable?
Yes. Corcept Therapeutics reported net income of $99.7 million in fiscal 2025, a net profit margin of 13.1%; its operating margin was 5.9%.
What is Corcept Therapeutics's gross margin?
Corcept Therapeutics's gross margin was 98.3% in fiscal 2025: for every $100 of revenue, Corcept Therapeutics kept $98 after the direct cost of its products and services.
How much does Corcept Therapeutics spend on research and development?
Corcept Therapeutics spent $254.9 million on research and development in fiscal 2025, 33.5% of revenue.
How fast is Corcept Therapeutics growing?
Revenue grew 16.6% a year on average over the last five fiscal years, from $353.9 million to $761.4 million.
What are Corcept Therapeutics's earnings per share?
Corcept Therapeutics earned $0.82 per diluted share in fiscal 2025, compared with $1.24 a year earlier.
When will Corcept Therapeutics report its next earnings?
Corcept Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 3, 2026.
When does Corcept Therapeutics's fiscal year end?
Corcept Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 24, 2026.